PHARMACY

PerceptiMed names new VP sales and marketing

BY David Salazar
MOUNTAIN VIEW, Calif. — Pharmacy technology company PerceptiMed on Monday announced the appointment of Terry Cater to the position of VP sales and marketing. 
 
“We are pleased that Terry has joined our operation to lead our sales and marketing efforts at this critical time of growth for PerceptiMed,” PerceptiMed founder Dr. Alan Jacobs said, “Terry’s skillsets will help to maximize the pilot programs that we have successfully completed, and to leverage that success in our sales channels as we establish a new industry standard for dispensing medication.”
 
Cater has worked in the chain drug, supermarket, drug wholesaling and healthcare technology sectors over the course of his career, most recently serving as director of pharmacy at Safeway Pharmacies and Save Mart Stores in California. He has held VP-level positions at Cardinal Health and McKesson, and has operated an independent pharmacy consultancy for 10 years. He is a member of the California Pharmacists Association and belongs to various national organizations, including the National Community Pharmacists Association. 
 
Perceptimed’s offerings, which include medication verification and dispensing technology IdentRx, and will-call solution scripClip, work to reduce dispensing errors in pharmacy. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves Aurobindo’s Micardis HCT generic

BY David Salazar
SILVER SPRING, Md. — The Food and Drug Administration has approved Aurobindo’s generic of Micardis HCT (telmisartan and hydrochlorothiazide) tablets, the company announced Friday. 
 
The drug is indicated to treat hypertension and had a market size of $81.9 million for the 12 months ended November 2016, according to QuintilesIMS data.  
 
Aurobindo’s generic will be available in dosage strengths of 40 mg telmistartan/12.5 mg hydrochlorothiazide, 80 mg telmisartan/12.5 mg hydrochlorothiazide and 8- mg telmisartan/25 mg hydrochlorothiazide. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Bristol-Myers Squibb decides against accelerated approval for Opdivo/Yervoy combo for lung cancer

BY David Salazar
PRINCETON, N.J. — Bristol-Myers Squibb has announced that it will not seek an accelerated regulatory approval for a combination of its Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for lung cancer. 
 
The company said the announcement was “based on a review of data available at this time,” and noted that they would not provide additional details to “protect the integrity of ongoing registrational studies.”
 
The Food and Drug Administration approved the regimen of Opdivo and Yervoy as a treatment for metastatic melanoma in October 2015. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?